contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


scandinavian-chemotech-secures-new-order-and-expands-animal-care-operations-through-global-collaboration-in-equine-oncology

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Scandinavian ChemoTech is a Swedish company that develops and markets medical technology based on electrochemotherapy for the treatment of cancer. The company offers systems and solutions to clinics in oncology and veterinary medicine and has operations in international markets, including India and Southeast Asia. The company was founded in 2015 and is headquartered in Lund, Sweden.

Scandinavian ChemoTech

Scandinavian ChemoTech continues to drive its Animal Care operations forward by securing yet another commercial collaboration with a global operator of equine hospitals, with an initial transaction...

<div class="abstract">Scandinavian ChemoTech continues to drive its Animal Care operations forward by securing yet another commercial collaboration with a global operator of equine hospitals, with an initial transaction valued at approximately EUR 45,000. This partnership strengthens the company's mission to revolutionize veterinary oncology with Tumor-Specific Electroporation (TSE). The group has grown to over 50 clinics across Europe and North America, employing 1,500+ professionals, with plans to gradually expand TSE to more locations.</div>After a long evaluation period, which included approximately 20 treatments of sarcoids and melanomas in horses, the hospital group-operating across the world-has agreed to gradually integrate TSE into its treatment offerings. This decision comes after witnessing the potential of the vetIQure™ TSE technology in addressing challenging equine tumors.The initial transaction includes a vetIQure™ system, comprising the vetIQure device and its specialized treatment kits. This marks the beginning of a long-term collaboration aimed at expanding the use of TSE in equine oncology. &nbsp;"We are very pleased to have concluded an extensive evaluation with a global equine hospital group that owns and operates hospitals in Scandinavia, many European countries, North America, and New Zealand," says Mohan Frick, CEO of Scandinavian ChemoTech.&nbsp;Scandinavian ChemoTech continues to expand its footprint in the veterinary sector, reinforcing its commitment to improving cancer treatments for both animals and humans. This latest collaboration further underscores the growing demand for innovative and effective oncology solutions in veterinary medicine. In addition to publicly announced orders, ChemoTech and its subsidiaries regularly receive undisclosed orders, as these are considered a natural part of ongoing business operations and company development and are therefore not deemed to have an impact on the share price.<div>This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on "Innehållet inom klamrarna kommer ersättas med rätt tid och datum vid utskickstillfället"&gt;21-03-2025 12:53 CET.</div>

Scandinavian ChemoTech Secures New Order and Expands Animal Care Operations Through Global Collaboration in Equine Oncology